UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors

Cell reports (Cambridge), 2019-03, Vol.26 (10), p.2651-2666.e6

2019

Link zum Volltext

Verfügbarkeit prüfen

A spatial map of hepatic mitochondria uncovers functional heterogeneity shaped by nutrient-sensing signaling

Nature communications, 2024-02, Vol.15 (1), p.1799-1799

2024

Link zum Volltext

Verfügbarkeit prüfen

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Cell reports. Medicine, 2020-04, Vol.1 (1), p.100007, Article 100007

2020

Link zum Volltext

Verfügbarkeit prüfen

Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2010-12, Vol.52 (6), p.2034-2043

2010

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response

Molecular & cellular proteomics, 2017-05, Vol.16 (5), p.891-910

2017

Link zum Volltext

Verfügbarkeit prüfen

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma

Cancer discovery, 2015-05, Vol.5 (5), p.534-549

2015

Link zum Volltext

Verfügbarkeit prüfen

Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance

Cancers, 2023-04, Vol.15 (8), p.2263

2023

Link zum Volltext

Verfügbarkeit prüfen

LKB1 acts as a critical brake for the glucagon‐mediated fasting response

Hepatology communications, 2022-08, Vol.6 (8), p.1949-1961

2022

Link zum Volltext

Verfügbarkeit prüfen

Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance

Cancer research (Chicago, Ill.), 2021-06, Vol.81 (11), p.3051-3066

2021

Link zum Volltext

Verfügbarkeit prüfen

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma

Molecular & cellular proteomics, 2021-01, Vol.20, p.100136-100136, Article 100136

2021

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V[S]

Molecular & cellular proteomics, 2019-04, Vol.18 (4), p.622-641

2019

Link zum Volltext

Verfügbarkeit prüfen

SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma

Oncogene, 2021-05, Vol.40 (18), p.3331-3346

2021

Link zum Volltext

Verfügbarkeit prüfen

Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer

Cancer research communications, 2024-02, Vol.4 (2), p.337-348

2024

Link zum Volltext

Verfügbarkeit prüfen

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models

Oncotarget, 2016-08, Vol.7 (34), p.54137-54156

2016

Link zum Volltext

Verfügbarkeit prüfen

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response

Cold Spring Harbor molecular case studies, 2016-11, Vol.2 (6), p.a001263-a001263

2016

Link zum Volltext

Verfügbarkeit prüfen

Genome-wide transcriptional sequencing identifies novel mutations in metabolic genes in human hepatocellular carcinoma

Cancer genomics & proteomics, 2014-01, Vol.11 (1), p.1-12

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1438: Integrated proteogenomics utilizing mass spectrometry to identify MHC-associated neopeptides in EGFR mutant lung adenocarcinoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1438-1438

2019

Link zum Volltext

Verfügbarkeit prüfen

Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant NSCLC

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9049-9049

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT106: Local ablative therapy for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT106-CT106

2018

Link zum Volltext

Verfügbarkeit prüfen

Mad1 Function Is Regulated through Elements within the Carboxy Terminus

Molecular and Cellular Biology, 2000-06, Vol.20 (12), p.4253-4264

2000

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V

Molecular & cellular proteomics, 2019-04, Vol.18 (4), p.622

2019

Link zum Volltext

Verfügbarkeit prüfen

Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation

Molecular and Cellular Biology, 1997-05, Vol.17 (5), p.2353-2359

1997

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of tumorigenicity in lung adenocarcinoma cells by c‐erbB‐2 antisense expression

International journal of cancer, 1997-08, Vol.72 (4), p.631-636

1997

Link zum Volltext

Verfügbarkeit prüfen

c-Myc inactivation by mutant max alters growth and morphology of NCI-H-630 colon cancer cells

Journal of cellular physiology, 1996-10, Vol.169 (1), p.200-208

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(33)
Dissertationen
(1)

Sprache

Englisch
(34)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(30)
MEDLINE
(24)
Ovid SocietyJournals and Single Titles
(10)
NUS Single-Journal Subscriptions
(10)
Wiley Blackwell Single Titles
(5)
Wiley Online Library
(4)
Ingenta
(4)
Nexis
(3)
Nature
(3)
IngentaConnect Journals
(2)
Taylor & Francis
(2)
ProQuest Dissertations & Theses A&I
(1)

7 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors

A spatial map of hepatic mitochondria uncovers functional heterogeneity shaped by nutrient-sensing signaling

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma

Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma

LKB1 acts as a critical brake for the glucagon‐mediated fasting response

Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma

Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V[S]

SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma

Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response

Genome-wide transcriptional sequencing identifies novel mutations in metabolic genes in human hepatocellular carcinoma

Abstract 1438: Integrated proteogenomics utilizing mass spectrometry to identify MHC-associated neopeptides in EGFR mutant lung adenocarcinoma

Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant NSCLC

Abstract CT106: Local ablative therapy for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib

Mad1 Function Is Regulated through Elements within the Carboxy Terminus

Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V

Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation

Inhibition of tumorigenicity in lung adenocarcinoma cells by c‐erbB‐2 antisense expression

c-Myc inactivation by mutant max alters growth and morphology of NCI-H-630 colon cancer cells

Suchergebnisse filtern